Silexion Therapeutics (SLXNW)

Silexion Therapeutics Corp a clinical-stage, oncology-focused biotechnology company engaged in the discovery and development of proprietary treatments for KRAS-driven cancers. The KRAS gene is an oncogene that is involved in the regulation of cell division as a result of its ability to relay external signals into the cell. Its product candidate, SIL204, consists of locally administered small interfering RNAs, or siRNA, in a solution, as a first-line treatment of locally advanced pancreatic cancer patients, or LAPC, in combination with standard-of-care chemotherapy. It is currently focused on treatment for pancreatic cancer tumors bearing the KRAS G12D or KRAS G12V mutations where metastases have not been detected and are non-resectable, i.e. it is not able to be surgically removed.

O preço atual da ação Silexion Therapeutics Corp Warrant (SLXNW) é de , refletindo uma variação de NaN% desde o abriu. A capitalização de mercado da empresa é de , com um volume de negociações diário de ações. O preço de fechamento anterior foi .

Pronto para começar? Siga os passos abaixo ou leia nosso guia sobre como comprar Silexion Therapeutics ações na Kraken a partir de 10 $.